Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039052 · ClinicalTrials.gov registry record · Phase 1
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
A Phase 1 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039052 is a Phase 1 study that has completed, run by Neurocrine Biosciences.
The verdict
NCT00039052, a Phase 1 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer that has not responded to previous treatment.
Interventions
- BIOLOGICAL interleukin-4 PE38KDEL cytotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039052
The ClinicalTrials.gov registry entry for NCT00039052 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which interleukin-4 PE38KDEL cytotoxin is the first listed.
NCT00039052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039052 about?
NCT00039052 is a clinical study titled "Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer". RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-smal...
What is the current status of trial NCT00039052?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00039052?
The interventions under investigation include: interleukin-4 PE38KDEL cytotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039052?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.